Study guide
2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy
CDR CSO Board Certified Specialist in Oncology Nutrition Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the CDR CSO Exam & Certification Logistics 1.2 How to Navigate and Master This Study Guide
2 Chapter 2: Cancer & Cancer Treatment Modalities
2.1 Cancer Biology, Pathophysiology, & Carcinogenesis 2.2 Staging, Grading, & Surgical Oncology Interventions 2.3 Radiation Therapy Modalities & Radiation Toxicities 2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging 2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy 2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)
3 Chapter 3: Comprehensive Nutrition Assessment & Malnutrition Staging
3.1 Patient-Generated Subjective Global Assessment (PG-SGA) 3.2 GLIM Criteria for Malnutrition Diagnosis in Oncology 3.3 Cancer Cachexia Staging & Pathophysiology (Fearon Consensus) 3.4 Estimating Energy & Protein Requirements (ESPEN Guidelines) 3.5 Anthropometrics & Body Composition Analysis (DEXA, BIA, CT) 3.6 Biochemical & Inflammatory Marker Interpretation 3.7 Nutrition-Focused Physical Exam (NFPE) in Oncology 3.8 Medical, Oncologic, and Treatment History Review 3.9 Diet and Lifestyle History: Methods and Interpretation 3.10 Cultural, Psychosocial, and Socioeconomic Factors
4 Chapter 4: Nutrition-Impact Side Effect Management & Pharmacotherapy
4.1 Upper GI Symptoms: Anorexia, Early Satiety, Nausea, & Vomiting 4.2 Oral & Mucosal Toxicities: Stomatitis, Mucositis, Dysgeusia, & Xerostomia 4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation 4.4 Pancreatic Exocrine Insufficiency & PERT Dosing Protocols 4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics 4.6 Oncologic Emergencies: Tumor Lysis, Hypercalcemia, & Superior Vena Cava Syndrome
5 Chapter 5: Specialized Nutrition Interventions, Disease-Site MNT & Care Coordination
5.1 Enteral Nutrition: Access, Indications, & Formula Selection 5.2 Prophylactic Enteral Tubes in Head & Neck Cancer 5.3 Parenteral Nutrition in Oncology: Indications & Management 5.4 Disease-Site MNT: Head & Neck, Esophageal, & Gastric Cancers 5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers 5.6 Disease-Site MNT: Hematologic Malignancies & HSCT 5.7 Refeeding Syndrome & Cyclic Nutrition Support Protocols 5.8 Referrals, Care Coordination, and Transitions of Care 5.9 Monitoring, Evaluation, and Nutrition Outcomes
6 Chapter 6: Patient Education, Counseling, & Herbal/Supplement Safety
6.1 Patient Counseling & Motivational Interviewing 6.2 Managing Sensory Alterations & Taste Changes 6.3 Complementary & Alternative Medicine (CAM) in Oncology 6.4 Dietary Supplement & Herbal Safety during Cancer Therapy 6.5 Key Drug-Nutrient Interactions in Oncology
7 Chapter 7: Cancer Survivorship, Palliative Nutrition, & End-of-Life Ethics
7.1 Food Safety & Neutropenic Dietary Evidence 7.2 Cancer Survivorship: AICR/WCRF Guidelines & Lifestyle 7.3 Weight Management & Metabolic Health in Survivorship 7.4 Palliative Nutrition & Goals of Care Alignment 7.5 End-of-Life Ethical Considerations & Bioethics
2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy
Key Takeaways Explain This Topic AI
Monoclonal antibodies (mAbs) target specific cell-surface receptors: Trastuzumab targets HER2 (requiring LVEF cardiotoxicity monitoring), Cetuximab targets EGFR (causing acneiform rash and severe renal magnesium wasting), and Rituximab targets CD20.
Oral tyrosine kinase inhibitors (TKIs, e.g., Imatinib, Erlotinib) block intracellular signaling cascades; administration requires strict food interaction management (e.g., avoiding grapefruit juice due to CYP3A4 enzyme inhibition).
Immune Checkpoint Inhibitors (ICIs targeting PD-1/PD-L1 or CTLA-4) trigger immune-related adverse events (irAEs), most notably immune-mediated colitis, severe watery diarrhea, and autoimmune thyroiditis.
CAR-T cell therapy carries a high risk for Cytokine Release Syndrome (CRS Grades 1–4) caused by a massive systemic inflammatory cytokine surge (IL-6, TNF-alpha), managed with Tocilizumab (anti-IL-6 receptor antibody).
ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) manifests during CAR-T therapy as expressive aphasia, encephalopathy, and tremors, requiring close neurological monitoring and prompt high-dose corticosteroid therapy.
Last updated: August 2026
2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy
Cancer therapeutics have evolved beyond traditional non-specific cytotoxic chemotherapy toward targeted agents and immunotherapies. Targeted therapies inhibit specific molecular drivers of malignant transformation, while immunotherapies harness the host's immune system to recognize and eliminate cancer cells. Despite improved target specificity, these novel agents induce unique, mechanism-based toxicities that require specialized medical nutrition management.
- Targeted Therapies: Monoclonal Antibodies & Small Molecules
- 1. Monoclonal Antibodies (mAbs)
Monoclonal antibodies are engineered proteins designed to bind specific extracellular tumor antigens or receptor tyrosine kinases.
Agent Target Receptor Primary Indications Key Toxicities & MNT Considerations
Trastuzumab HER2 / neu (ERBB2) HER2-positive Breast Cancer, HER2-positive Gastric Adenocarcinoma Cardiotoxicity: Decreases left ventricular ejection fraction (LVEF); unlike anthracyclines, trastuzumab cardiotoxicity is generally non-dose-dependent and reversible upon drug discontinuation. Mandatory ECHO every 3 months.
Cetuximab EGFR (Epidermal Growth Factor Receptor) Metastatic Colorectal Cancer, Head & Neck Squamous Cell Carcinoma Acneiform Skin Rash: Correlates with treatment response.; Severe Hypomagnesemia: EGFR inhibition in renal distal convoluted tubule impairs TRPM6 magnesium reabsorption, causing profound magnesium wasting requiring regular IV/oral Mg replacement.
Rituximab CD20 (B-lymphocyte surface antigen) Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Infusion reactions, hypogammaglobulinemia, hepatitis B reactivation.
2. Tyrosine Kinase Inhibitors (TKIs)
TKIs are orally bioavailable small-molecule inhibitors that enter target cells and bind to the ATP-binding pocket of intracellular tyrosine kinase domains, blocking downstream signal transduction.
Imatinib: Inhibits BCR-ABL (Philadelphia chromosome in CML) and c-KIT (Gastrointestinal Stromal Tumors [GIST]). Toxicities include periorbital edema, fluid retention, nausea, diarrhea, and muscle cramps. MNT: Take with meals and a large glass of water to minimize GI irritation.
Erlotinib / Osimertinib: Inhibits EGFR kinase in non-small cell lung cancer (NSCLC). Toxicities include severe diarrhea, stomatitis, and anorexia.
Drug-Food Interactions (CYP3A4 Inhibition): Most oral TKIs are metabolized by hepatic CYP3A4 enzymes . Co-ingestion of grapefruit, grapefruit juice, Seville oranges, or starfruit inhibits CYP3A4, causing toxic systemic TKI drug accumulation. Conversely, St. John's Wort induces CYP3A4, reducing TKI efficacy.
Immune Checkpoint Inhibitors (ICIs) & irAEs
Immune Checkpoint Inhibitors block inhibitory signaling pathways (checkpoints) that tumors exploit to evade T-cell mediated destruction. +---------------------------------------------------------------------------------------------------------+
- | IMMUNE CHECKPOINT INHIBITOR CLASSES |
- | 1. PD-1 Inhibitors: Pembrolizumab, Nivolumab (bind PD-1 receptor on T-cells). |
- | 2. PD-L1 Inhibitors: Atezolizumab, Durvalumab (bind PD-L1 ligand on tumor cells). |
- | 3. CTLA-4 Inhibitors: Ipilimumab (binds CTLA-4 on T-cells to enhance early T-cell activation). |
- +---------------------------------------------------------------------------------------------------------+
- Immune-Related Adverse Events (irAEs)
Unbraking T-cell activity can cause autoimmune tissue destruction across any organ system, termed immune-related adverse events (irAEs) .
Immune-Mediated Colitis & Diarrhea: Most frequent severe GI irAE (common with ipilimumab or combination PD-1/CTLA-4 blockade). Manifests as severe watery diarrhea (>6 stools/day above baseline), abdominal pain, hematochezia, and mucosal ulceration on colonoscopy.
Management: Rule out infectious etiologies (C. difficile, CMV). Grade 1: Symptomatic anti-motility therapy. Grade 2–4: Immediate holding of ICI and high-dose systemic corticosteroids (prednisone 1–2 mg/kg/day or IV methylprednisolone). If refractory: Infliximab (anti-TNF alpha) or Vedolizumab.
MNT: Low-residue, low-fat, lactose-free diet; aggressive electrolyte repletion; parenteral nutrition if corticosteroid-refractory severe colitis requires prolonged bowel rest.
Endocrinopathies: Autoimmune hypophysitis, thyroiditis (primary hypothyroidism or hyperthyroidism), and autoimmune Type 1 Diabetes Mellitus. MNT: Monitor thyroid panel (TSH, free T4) and blood glucose; initiate levothyroxine or insulin as indicated.
CAR-T Cell Therapy: CRS & ICANS
Chimeric Antigen Receptor (CAR) T-Cell Therapy is an autologous cellular immunotherapy. Patient T-cells are harvested via leukapheresis, genetically engineered via viral vectors to express a CAR targeting a specific tumor antigen (e.g., CD19 in B-cell ALL/lymphoma or BCMA in Multiple Myeloma), expanded ex vivo, and re-infused into the patient following lymphodepleting chemotherapy (fludarabine + cyclophosphamide). +---------------------------------------------------------------------------------------------------------+
- | CAR-T CELL THERAPY WORKFLOW |
- | Leukapheresis -> T-Cell Isolation -> CAR Gene Transduction -> Ex Vivo Expansion -> Lymphodepletion |
- | -> Infusion of CAR-T Cells -> In Vivo Expansion -> Targeted Tumor Lysis + Cytokine Surge |
- +---------------------------------------------------------------------------------------------------------+
- 1. Cytokine Release Syndrome (CRS)
As infused CAR-T cells encounter target tumor antigens, they undergo massive in vivo clonal expansion and release immense quantities of inflammatory cytokines—specifically Interleukin-6 (IL-6) , Interferon-gamma (IFN-g), and Tumor Necrosis Factor-alpha (TNF-a).
CRS Grade Clinical Features Medical & Nutrition Management
Grade 1 Fever (temp >=38.0°C); no hypotension, no hypoxia. Symptomatic support; antipyretics; oral nutritional supplements as tolerated.
Grade 2 Fever with hypotension responding to fluids/low-dose vasopressor; hypoxia responding to low-flow oxygen (nasal cannula). Administer Tocilizumab (anti-IL-6 receptor mAb); IV fluid boluses; monitor oral intake.
Grade 3 High fever; hypotension requiring high-dose vasopressors; hypoxia requiring high-flow oxygen. Tocilizumab + IV Corticosteroids (Dexamethasone); transfer to ICU; initiate Enteral/Parenteral Nutrition if oral intake compromised >5–7 days.
Grade 4 Life-threatening hypotension requiring multiple vasopressors; mechanical ventilation required. High-dose steroids + immunosuppressants; ICU care; Parenteral Nutrition (TPN) if gut hypoperfused.
2. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
ICANS is a neuropsychiatric toxicity caused by cytokine-mediated blood-brain barrier disruption and central nervous system inflammation. Manifestations include expressive aphasia (loss of speech fluency; early pathognomonic sign), dysgraphia (inability to write), tremors, confusion, seizures, and cerebral edema.
Clinical Assessment: Evaluated daily using the ICE (Immune Effector Cell Encephalopathy) score (evaluating orientation, naming, writing, following commands).
Management: High-dose IV dexamethasone; seizure prophylaxis (levetiracetam); continuous neurological monitoring. MNT: Maintain enteral nutrition access (nasogastric/nasojejunal tube) if dysphagia or encephalopathy impairs safe oral swallowing.